These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 30906568)

  • 1. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
    Alqahtani A; Choucair K; Ashraf M; Hammouda DM; Alloghbi A; Khan T; Senzer N; Nemunaitis J
    Future Sci OA; 2019 Mar; 5(3):FSO372. PubMed ID: 30906568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
    To KKW; Xing E; Larue RC; Li PK
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
    Chaidos A; Caputo V; Karadimitris A
    Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
    Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G
    Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics.
    Halder TG; Soldi R; Sharma S
    Curr Opin Oncol; 2021 Sep; 33(5):526-531. PubMed ID: 34280171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.
    Abedin SM; Boddy CS; Munshi HG
    Onco Targets Ther; 2016; 9():5943-5953. PubMed ID: 27729803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting BET bromodomain proteins in solid tumors.
    Sahai V; Redig AJ; Collier KA; Eckerdt FD; Munshi HG
    Oncotarget; 2016 Aug; 7(33):53997-54009. PubMed ID: 27283767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors.
    Wadhwa E; Nicolaides T
    Cureus; 2016 May; 8(5):e620. PubMed ID: 27382528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.
    Reyes-Garau D; Ribeiro ML; Roué G
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31581671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN.
    Shi X; Wang Y; Zhang L; Zhao W; Dai X; Yang YG; Zhang X
    Front Cell Dev Biol; 2022; 10():1021820. PubMed ID: 36187481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
    Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
    ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
    Wahi A; Manchanda N; Jain P; Jadhav HR
    Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members.
    Malik N; Vollmer S; Nanda SK; Lopez-Pelaez M; Prescott A; Gray N; Cohen P
    Biochem J; 2015 Jun; 468(3):363-72. PubMed ID: 25891802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.
    Humphreys PG; Anderson NA; Bamborough P; Baxter A; Chung CW; Cookson R; Craggs PD; Dalton T; Fournier JCL; Gordon LJ; Gray HF; Gray MW; Gregory R; Hirst DJ; Jamieson C; Jones KL; Kessedjian H; Lugo D; McGonagle G; Patel VK; Patten C; Poole DL; Prinjha RK; Ramirez-Molina C; Rioja I; Seal G; Stafford KAJ; Shah RR; Tape D; Theodoulou NH; Tomlinson L; Ukuser S; Wall ID; Wellaway N; White G
    J Med Chem; 2022 Nov; 65(22):15174-15207. PubMed ID: 36378954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials.
    Sun Y; Han J; Wang Z; Li X; Sun Y; Hu Z
    Front Pharmacol; 2020; 11():621093. PubMed ID: 33574760
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives.
    Feng L; Wang G; Chen Y; He G; Liu B; Liu J; Chiang CM; Ouyang L
    Med Res Rev; 2022 Mar; 42(2):710-743. PubMed ID: 34633088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.